ÀϹݿ¬Á¦ : ºÎÀÎÁ¾¾çÇÐ |
- ÀϽà : 2016³â 9¿ù 23ÀÏ (±Ý)
- Àå¼Ò : ¿¡¸Þ¶öµåȦ B[3F] |
GO01-GO05 (08:20~09:10) |
ÁÂÀå : ±è¿ë¹ü(¼¿ïÀÇ´ë) |
GO0108:20~08:30 |
±âÀº¿µ °¡Å縯ÀÇ´ë ¼¿ï¼º¸ðº´¿ø »êºÎÀΰú |
Immunocytochemistry negativity for human papillomavirus L1 capsid protein as a biomarker in atypical squamous cell of undetermined significance or low grade squamous intraepthelial lesion |
GO0208:30~08:40 |
È«¿µÈñ °Ç±¹´ëÇб³º´¿ø »êºÎÀΰú |
Impact of Adjuvant Hysterectomy on Prognosis in Patients with Locally Advanced Cervical
Cancer Treated with Definitive Chemoradiation: A Meta-Analysis |
GO0308:40~08:50 |
°¼º¿ì ¾ÆÁÖ´ëÇб³º´¿ø »êºÎÀΰú |
Treatment outcomes in patients with FIGO stage IB-IIA cervical cancer and a focally disrupted cervical stromal ring on magnetic resonance imaging: a propensity score matching study |
GO0408:50~09:00 |
ÀÌÀοÁ ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Uniformed Indocynine Green injection protocol; the effective factor of increasing optimal sentinel lymph node mapping rate in cervical and endometrial cancers |
GO0509:00~09:10 |
ÀÌÁöÇý °Ç±¹´ëÇб³º´¿ø »êºÎÀΰú |
Prediction model for para-aortic lymph node metastasis in patients with locally advanced
cervical cancer |
GO06-GO10 (09:10~10:00) |
ÁÂÀå : ±è¿µÅ¹(¿ï»êÀÇ´ë) |
GO0609:10~09:20 |
¾î°æÁø ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Germline Mutations in Patients with Epithelial Ovarian Cancer using Gene-Panel Sequencing: Beyond BRCA 1/2 |
GO0709:20~09:30 |
À̽ÅÈ ¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø »êºÎÀΰú |
Potential urinary biomarker panel to predict malignancy in women with pelvic masses |
GO0809:30~09:40 |
±Ç¿ëÀÏ À¯·ÎÁø»êºÎÀΰú |
Glycan Markers for Ovarian Cancer with High Sensitivity and High Specificity |
GO0909:40~09:50 |
ÀÌÁ¤¿ø ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Anti-cancer Effect of Ulipristal Acetate in Uterine Leiomyosarcoma |
GO1009:50~10:00 |
ÀÌ½Â¹Ì ¼¿ï´ëÇб³º´¿ø »êºÎÀΰú |
Development of a female animal model for anatomical and functional assessment of the
pelvic autonomic nerves in women |
GO11-GO15 (10:30~11:20) |
ÁÂÀå : Çã¼ö¿µ(°¡Å縯ÀÇ´ë) |
GO1110:30~10:40 |
±èÈñÁ¤ ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Long non-coding RNA HOXA11 antisense promotes tumor progression and predicts patient prognosis in serous ovarian cancer |
GO1210:40~10:50 |
¹éÀ̼± ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
The Effect of Chemical inhibition of Lysyl-tRNA Synthase-Laminin Receptor in Ovarian Cancer |
GO1310:50~11:00 |
À±Á¤¼ö °æºÏ´ëÇб³º´¿ø »êºÎÀΰú |
The long non-coding RNAs in the epithelial recurrent ovarian cancer |
GO1411:00~11:10 |
±èÈñÁ¤ ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Steroid Receptor Activator modulates proliferation and invasion in the human cervical cancer |
GO1511:10~11:20 |
¼µ¿¼ö ºÎ»ê´ëÇб³º´¿ø »êºÎÀΰú |
Selective cytotoxic effect of non-thermal micro-DBD plasma in uterine cervical cancer cells |
GO16-GO20 (11:20~12:10) |
ÁÂÀå : ÀÌÀ±¼ø(°æºÏÀÇ´ë) |
GO1611:20~11:30 |
¾î°æÁø ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
Long Term Survival Analysis of Carboplatin or Cisplatin Based Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients |
GO1711:30~11:40 |
À±¹ÎÁ¤ ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Dose-dense paclitaxel and carboplatin for ovarian carcinoma among Korean population: single institution experience |
GO1811:40~11:50 |
±è¹Ì¼± ¼¿ï´ëÇб³ ºÐ´çº´¿ø »êºÎÀΰú |
Survival impact of low anterior resection in the patients with epithelial ovarian cancer grossly confined to pelvic cavity: A multicenter retrospective study |
GO1911:50~12:00 |
°ûÀ翵 ¿ï»ê´ëÇб³º´¿ø »êºÎÀΰú |
Adjuvant treatment strategy of pathological down-staged patients after radical surgery of locally advanced cervical cancer with neoadjuvant chemotherapy |
GO2012:00~12:10 |
¿ÀÁøÁÖ ´ë±¸°¡Å縯´ëÇб³º´¿ø »êºÎÀΰú |
The cutoff level of serum squamous cell carcinoma antigen to detect recurrent cervical squamous cell carcinoma during post-treatment surveillance |
GO21-GO24 (12:10~12:50) |
ÁÂÀå : ±èÀçÈÆ(¿¬¼¼ÀÇ´ë) |
GO2112:10~12:20 |
±Ç¹ÎÁ¤ ¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø »êºÎÀΰú |
Rapid genetic screening experience among endometrial cancer about Lynch syndrome by
surgeon |
GO2212:20~12:30 |
À¯Áö±Ù °¡Å縯ÀÇ´ë ¼¿ï¼º¸ðº´¿ø »êºÎÀΰú |
Prevalence and outcome of BRCA mutation in Korean epithelial ovarian cancer women |
GO2312:30~12:40 |
ÀÓ¿µ¹Ì ÀÌÈ¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐºÎ¼Ó ¸ñµ¿º´¿ø »êºÎÀΰú |
Hypermethylation of the Single-minded homolog 1 (SIM1) as a novel biomarker for cervical
cancer screening |
GO2412:40~12:50 |
ÀåÅÂ±Ô °è¸íÀÇ´ë µ¿»êÀÇ·á¿ø »êºÎÀΰú |
Natural course of HPV positive women in Atypical Squamous Cells of Undetermined Significance or Low-Grade Squamous Intraepithelial Lesion and association of HPV genotype : HPV cohort study |
GO25-GO27 (14:00~14:30) |
ÁÂÀå : ¹®Çý¼º(ÀÌÈÀÇ´ë) |
GO2514:00~14:10 |
±è¼ö¿µ °í·ÁÀÇ´ë ¾È¾Ïº´¿ø »êºÎÀΰú |
Investigation of physician awareness regarding treatment options for cervical intraepithelial neoplasia 1 by using a survey questionnaire |
GO2614:10~14:20 |
À̹æÇö ÇѸ²ÀÇ´ë °µ¿¼º½Éº´¿ø »êºÎÀΰú |
Efficacy of the multidisciplinary tumor board conference in gynecologic oncology: A prospective study |
GO2714:20~14:30 |
Á¤¿µ½Å ¿¬¼¼´ëÇб³ ¼¼ºê¶õ½ºº´¿ø »êºÎÀΰú |
A sufficient number of relevant ethnic controls are needed for accurate assessment according to the ACMG standards and guidelines |
GO28-GO30 (14:30~15:00) |
ÁÂÀå : ±èÈ«¹è(ÇѸ²ÀÇ´ë) |
GO2814:30~14:40 |
ÃÖÀºÁö ÀÌÈ¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐºÎ¼Ó ¸ñµ¿º´¿ø »êºÎÀΰú |
One institute experience of Robotic Single-Site Surgery, 300 Cases
|
GO2914:40~14:50 |
¹ÚÁöÀº °æºÏ´ëÇб³º´¿ø »êºÎÀΰú |
Robotic infrarenal paraaortic lymphadenectomy with single-positioning approach using da Vinci Xi system: Initial experiences and comparison with dual-positioning approach using da Vinci S system |
GO3014:50~15:00 |
ÃÖÂ÷Çö ¼º±Õ°üÀÇ´ë °ºÏ»ï¼ºº´¿ø »êºÎÀΰú |
Usefulness of hemostatic agents for minimizing ovarian damage during laparoscopic
cystectomy for endometriosis |